Menu Menu Menu
Login Login Log in Search Search Search

AXA Framlington Biotech Class Z - Accumulation (GBP)

Sell:319.40p Buy:319.40p Change: 11.40p (3.45%)
Prices as at 28 June 2017
Sell:319.40p
Buy:319.40p
Change: 11.40p (3.45%)
You can buy or sell holdings in this fund through an ISA, Lifetime ISA, SIPP or Fund & Share Account
Prices as at 28 June 2017
Sell:319.40p
Buy:319.40p
Change: 11.40p (3.45%)
Prices as at 28 June 2017
You can buy or sell holdings in this fund through an ISA, Lifetime ISA, SIPP or Fund & Share Account
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.
Also available as income units Help

Charges and Savings

Initial charges
Initial charge: 0.00%
Initial saving from HL: 0.00%
HL dealing charge: Free
Net initial charge: 0.00%
Annual charges
Performance fee: No  
Ongoing charge (OCF/TER): 0.82%
Ongoing saving from HL: 0.00%
Net ongoing charge: 0.82%
There are other unit types of this fund available:
Inclusive - Class R - Income (GBP) (Net ongoing charge 0.82%)
Inclusive - Class R - Accumulation (GBP) (Net ongoing charge 0.82%)
Class Z - Income (GBP) (Net ongoing charge 0.82%)

In some cases the ongoing savings are provided by our loyalty bonus. Loyalty bonuses are tax-free in an ISA or SIPP. However, they may be subject to tax in a Fund & Share Account which would, in effect, reduce their value and increase the net ongoing charge.


Other Information

Unit type: Unbundled
Manager:
Linden Thomson
Fund launch date: 26 November 2001
Sector: Specialist
Fund size: £492 million
Number of holdings: 58
Fund type: Unit Trust
Accumulation/income: Accumulation
Dealing frequency: Daily
Valuation point: 12:00
Trustee: The National Westminster Bank plc
Minimum investment: £100.00
Charges deducted from: Income
Available in a regular savings plan: Yes
Minimum regular savings value: £25.00

Performance

28/06/12 to 28/06/13 28/06/13 to 28/06/14 28/06/14 to 28/06/15 28/06/15 to 28/06/16 28/06/16 to 28/06/17
Annual return 37.07% 33.79% 62.37% -27.78% 33.08%

Please remember past performance is not a guide to future returns. Where no data is shown, figures are not available. This information is provided to help you choose your own investments, remember they can fall as well as rise in value so you may not get back the original amount invested.

View fund chart

Our view on this fund

The Wealth 150 is the list of what we believe are the best funds in each sector. If a fund is not within our Wealth 150 this is not necessarily a recommendation to sell. However, if you are thinking of adding to your investments we believe Wealth 150 funds are superior alternatives. View funds on the Wealth 150 »

Fund Objective

To provide long term capital appreciation by investing principally in equity securities of companies in the biotechnology, genomics and medical research industries worldwide.

Income Details

Income paid: Bi-annually
Type of payment: Dividend
Ex-dividend date: 1 September 2017 1 March 2018
Payment date: 31 October 20174 30 April 20184

All yields are variable and not guaranteed. There is currently no yield information available for this fund.

Sector Weight
Pharmaceuticals & Biotechnology 95.09%
Cash and Equiv. 2.47%
Health Care Equipment & Services 1.95%
Non-Classified 0.49%
Country Weight
United States 81.38%
United Kingdom 4.48%
France 3.39%
Sweden 2.80%
Belgium 2.76%
Cash and Equiv. 2.47%
Ireland 1.17%
Switzerland 0.70%
Germany 0.43%
Canada 0.42%

Prices provided by Morningstar, correct as at 28 June 2017. Data provided by Funds Library, correct as at 31 May 2017.

FundsLibrary

You can buy or sell holdings in this fund through an ISA, Lifetime ISA, SIPP or Fund & Share Account

Data received from the Fund Management Company administering this fund and provided to you for your information. Hargreaves Lansdown accepts no liability for the reliability or accuracy of the data provided by third parties.

4 If you elect to receive the income from a Vantage ISA or Vantage Fund & Share Account, we will collect any dividends for you and then pay them directly into your bank account within the first 10 working days of the following month.